Kirk Ways

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA.

Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Norwest Venture Partners is a venture capital division of Norwest Partners founded in 1961. The firm is headquartered in Palo Alto, California with additional offices in Mumbai and Herzliya.

Johnson & Johnson Pharmaceutical Research & Development LLC provides research and development support services. It offers drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. The company is headquartered in Raritan, NJ.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY.

Part of Astellas Pharma, Inc., Astellas US LLC is a company that manufactures and markets pharmaceutical products. The company is based in Northbrook, IL. The CEO of the company is Kenji Yasukawa.

Illinois Biotechnology Industry Organization, also known as ibio, is a state trade association representing the life sciences industry in Illinois. The non-profit company is based in Chicago, IL. The organization's mission is to promote, connect, and engage the life sciences community to drive discovery, transform lives through groundbreaking research, and grow the economy. The company's membership ranges from corporations to startup companies in the biopharma, medical device, and nutrition industries. The Illinois life sciences industry is recognized as a national leader, and ibio's members are committed to expanding the boundaries of science by discovering, developing, and delivering innovative and needed therapeutics and products to transform patients' lives.

Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA.

Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US.

MDLIVE, Inc. operates as a telehealth provider of online and on-demand healthcare delivery services and software. Its cloud-based virtual medical office software platform enables patients, medical professionals, and plan administrators to collaborate through voice, video, email, and mobile devices; and allows payers and providers to collect and share clinical data from patient medical records, lab results, and in-home biometric devices for real-time risk assessments, wellness advice, diagnosis, and treatment. The company was founded by Randy Parker and Steven Victor Gurland in 2009 and is headquartered in Sunrise, FL.

Ziarco Group Ltd. operates as a clinical-stage biotechnology company that develops therapeutics targeting inflammatory skin diseases. The firm engages in development of novel treatments in dermatology. The company was incorporated on March 10, 2014 and is headquartered in Canterbury, the United Kingdom.

Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA.

Aristea Therapeutics, Inc. operates as a clinical-stage drug development company. It develops novel therapies to treat serious inflammatory diseases. The company was founded by James Morrison MacKay in 2018 and is headquartered in Poway, CA.

MBX Biosciences, Inc. operates as a preclinical-stage biotech company. It creates therapies to treat rare endocrine diseases. The company was founded by Peter Kent Hawryluk and Timothy Knickerbocker and is headquartered in Carmel, IN.

Plexium, Inc. provides drug development methodology services. It specializes in immunomodulation as a therapeutic approach for CNS and oncology. The company was founded by Brian Paegel on July 12, 2017 and is headquartered in San Diego, CA.

Curzion Pharmaceuticals, Inc. operates as a pharmaceutical firm. The company is headquartered in San Diego, CA.

Allievex Corp. operates as a biotechnology company. It develops therapies for the treatment of rare pediatric neurodegenerative diseases. The company was founded by Thomas P. Mathers and Eric H. Zanelli and is headquartered in Marblehead, MA.

Sparrow Pharmaceuticals, Inc. engages in pharmaceuticals industry. It develops drugs for cushing?s syndrome. The company was founded by David A. Katz and is headquartered in Portland, OR.

IFM Cinque, Inc. is a biotechnology company. The company is headquartered in Boston, MA.

IFM Continua, Inc. engages in the provision of biotechnology services. The company is headquartered in Boston, MA.

IFM Quattro, Inc. is a biotechnology company. The company is headquartered in Boston, MA.

Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022.

Invest Europe is a Belgian company that operates as a private equity, venture capital and infrastructure investment company. The company is based in Brussels, Belgium.

Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation.

Rezo Therapeutics, Inc. is a drug discovery company based in San Francisco, CA. The company's mission is to revolutionize traditional drug development by integrating proteomics, genetics, structural biology, chemistry, artificial intelligence, and machine learning to create maps of molecular disease networks. Rezo's initial focus is on oncology, but they plan to explore additional therapeutic areas through collaborations and partnerships. The company was founded by Natalia Jura, Kevan Shokat, Nevan Krogan, Sourav Bandyopadhyay, Norbert W. Bischofberger, and George A. Scangos, with Nevan Krogan serving as CEO since incorporation.